Jonathan McNeill - 15 Dec 2025 Form 4 Insider Report for CRESCENT BIOPHARMA, INC. (GLYC)

Reporting relationship: President and COO
Issuer ticker: GLYC
Reported as of: 15 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Dec 2025, 16:43:02 UTC
Prior SEC filing: 10 Dec 2025
Next SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Barbara Bispham, as attorney-in-fact for Jonathan McNeill

Key filing fact

Jonathan McNeill filed Form 4 for CRESCENT BIOPHARMA, INC. (GLYC) on 17 Dec 2025.

Key facts

This page summarizes Jonathan McNeill's Form 4 filing for CRESCENT BIOPHARMA, INC. (GLYC).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Dec 2025, 16:43.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001824673 Primary reporting owner

McNeill Jonathan

Relationship: President and COO
Address: C/O CRESCENT BIOPHARMA, INC., 300 FIFTH AVENUE, WALTHAM
Signature: /s/ Barbara Bispham, as attorney-in-fact for Jonathan McNeill
Signature date: 17 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CBIO transaction

Ordinary Shares

Award

Transaction value
Shares: +19,507
Change %: +15%
Price
Shares after: 153,707
Date: 15 Dec 2025
Ownership: Direct
Footnotes: F1

CBIO transaction

Ordinary Shares

Award

Transaction value
Shares: +6,000
Change %: +3.9%
Price
Shares after: 159,707
Date: 15 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +78,029
Change %
Price: $0.000000
Shares after: 78,029
Date: 15 Dec 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 78,029
Exercise price: $13.21
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.

Footnote F2

This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.